Vigil Neuroscience Inc (VIGL) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: N/A
• EPS Growth: 3.01%
• Country: US
• Employees: N/A
• Sector: N/A
• Sector Strength: N/A
• Industry: N/A
• EPS (TTM): N/A
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Vigil Neuroscience Inc's stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.

Vigil Neuroscience Inc Business Overview & Revenue Model

Company Description

Vigil Neuroscience Inc (VIGL) is a biotechnology company focused on the development of novel therapeutics for neurodegenerative diseases. Operating within the healthcare and life sciences sectors, the company is dedicated to harnessing the power of microglia, the brain's resident immune cells, to develop innovative treatments aimed at improving the lives of patients suffering from debilitating neurological conditions. Vigil Neuroscience's core products are in various stages of clinical development, targeting diseases with high unmet medical needs.

How the Company Makes Money

Vigil Neuroscience Inc generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments, research and development funding, and royalties on future product sales. The company may also secure grants and funding from governmental or non-governmental organizations to support its research initiatives. Additionally, as its products progress through clinical trials and reach commercialization, Vigil Neuroscience may generate revenue from the direct sales of its therapeutic products. However, as of the latest available data, the company is likely still in the pre-revenue stage, focusing heavily on research and development activities.

Vigil Neuroscience Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Vigil Neuroscience Inc Technical Analysis

• Last Price: ―

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIGL, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for VIGL.

Vigil Neuroscience Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	157.38M	-0.95	-58.95%	―	-72.45%	-28.60%
XCUR	48 Neutral	24.26M	-2.27	0.00%	―	-100.00%	64.16%
IMAB	45 Neutral	300.14M	-5.34	0.00%	―	-100.00%	72.53%
ACHV	37 Underperform	144.12M	-1.93	0.00%	―	0.00%	-32.50%
VIGL	35 Underperform		―		―	―	3.01%
UNCY	28 Underperform	69.94M	-1.17	0.00%	―	0.00%	68.02%
Sector *	―				―